#1 Clinical Trials Search in Europe

Human Igg1 Monoclonal Antibody Against Trem2

A groundbreaking clinical trial is underway to evaluate the long-term safety, tolerability, and effectiveness of AL002, a Human IgG1 Monoclonal Antibody Against TREM2, in patients with Alzheimer’s disease. This multicenter study aims to provide valuable insights into a potential new treatment option for this devastating neurological condition. The trial focuses on participants who have completed a previous AL002 study and will assess various aspects of the drug’s performance over an extended period.

Table of Contents

What is AL002?

AL002 is a new medication being studied for the treatment of Alzheimer’s disease. It is classified as a Human IgG1 Monoclonal Antibody Against TREM2. This means it’s a type of protein that has been designed to target a specific part of the immune system in the brain[1].

AL002 is also known by several other names, including:

  • Human IgG1 monoclonal antibody against Triggering Receptor Expressed on Myeloid Cells 2
  • Anti-TREM2 monoclonal IgG G1m17,1 kappa monoclonal antibody

How Does AL002 Work?

AL002 works by targeting a specific protein in the brain called TREM2 (Triggering Receptor Expressed on Myeloid Cells 2). This protein is found on certain immune cells in the brain and is thought to play a role in the progression of Alzheimer’s disease. By interacting with TREM2, AL002 aims to modify the immune response in the brain, potentially slowing down the progression of Alzheimer’s disease[1].

Clinical Trial Information

AL002 is currently being studied in a Phase 2 clinical trial. This means that while it has shown promise in earlier studies, it is still considered experimental and is not yet approved for general use. The main goal of this trial is to evaluate the long-term safety, tolerability, and effectiveness of AL002 in people with Alzheimer’s disease[1].

In this study:

  • Participants receive AL002 every 4 weeks through an intravenous (IV) infusion. This means the medication is given directly into a vein[1].
  • The study is looking at how safe AL002 is when used over a long period and how well people tolerate it[1].
  • Researchers are also studying how AL002 affects various markers of Alzheimer’s disease in the body and brain[1].

Eligibility Criteria

Not everyone with Alzheimer’s disease can participate in this study. Some key eligibility criteria include:

  • Participants must have completed a previous study of AL002 without having to stop the treatment early for safety reasons[1].
  • Participants need to have a study partner who can provide information about their condition[1].
  • There are specific weight and body mass index (BMI) requirements[1].
  • Participants must not be taking certain other medications or treatments for Alzheimer’s disease[1].

Safety and Monitoring

The safety of participants is a top priority in this study. Several measures are in place to monitor for any potential side effects or safety concerns:

  • Regular check-ups including physical exams, neurological exams, and laboratory tests[1].
  • Brain scans (MRI) to check for any changes in the brain[1].
  • Close monitoring for a condition called ARIA (Amyloid-Related Imaging Abnormalities), which can occur with some Alzheimer’s treatments[1].

Potential Benefits and Risks

As with any experimental treatment, there are potential benefits and risks to consider:

Potential benefits:

  • AL002 may help slow down the progression of Alzheimer’s disease, although this is not yet proven[1].
  • Participants contribute to the advancement of Alzheimer’s research[1].

Potential risks:

  • As an experimental treatment, there may be unknown side effects[1].
  • The treatment may not be effective for everyone[1].
  • There are risks associated with the IV infusion and frequent medical procedures[1].

It’s important to note that AL002 is still in the research phase. While it shows promise, more studies are needed to fully understand its effectiveness and safety in treating Alzheimer’s disease. If you’re interested in learning more about this treatment or participating in clinical trials, it’s best to discuss this with your healthcare provider[1].

Aspect Details
Study Type Phase 2 Clinical Trial, Long-term Extension Study
Drug Name AL002 (Human IgG1 Monoclonal Antibody Against TREM2)
Condition Alzheimer’s Disease
Administration Intravenous infusion every 4 weeks
Primary Objectives Evaluate long-term safety, tolerability, and efficacy
Key Assessments Adverse events, vital signs, clinical laboratory tests, MRI, optional PET imaging
Eligibility Completed previous AL002-2 study, meet weight and BMI criteria, have a study partner
Duration Up to 48 weeks of treatment

FAQ

  • What is AL002 and how does it work? AL002 is a Human IgG1 Monoclonal Antibody that targets TREM2 (Triggering Receptor Expressed on Myeloid Cells 2). It is designed to potentially treat Alzheimer's disease by interacting with the immune system in the brain. The exact mechanism is still being studied, but it's believed to help reduce inflammation and improve brain cell function.
  • Who is eligible to participate in this clinical trial? Participants who have completed the planned treatment period in the previous AL002-2 study are eligible. They must not have prematurely discontinued the study drug in that trial. Other criteria include weight requirements, availability of a study partner, and willingness to comply with contraception guidelines.
  • How is the medication administered in this trial? AL002 is administered every 4 weeks via intravenous (IV) infusion. This means the medication is given directly into the bloodstream through a vein.
  • What are the main objectives of this clinical trial? The main objectives are to evaluate the long-term safety and tolerability of AL002 in participants with Alzheimer's disease. The study also aims to assess the effect of the body's immune response to AL002 on its safety, how it moves through the body (pharmacokinetics), and its effects on biological markers.
  • What kind of tests and assessments will participants undergo? Participants will undergo various assessments, including monitoring for adverse events, vital signs checks, clinical laboratory tests, physical and neurological examinations, ECGs, and MRI scans. Some participants may also have the option to participate in PET imaging to assess brain changes related to Alzheimer's disease.

Ongoing Clinical Trials on Human Igg1 Monoclonal Antibody Against Trem2

  • Study on the Long-term Safety and Effects of AL002 and Florquinitau F18 in Patients with Alzheimer’s Disease

    Not recruiting

    2 1
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

Glossary

  • Alzheimer's Disease (AD): A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • TREM2: Triggering Receptor Expressed on Myeloid Cells 2, a protein involved in the immune response in the brain and believed to play a role in Alzheimer's disease.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They can be used to detect or treat diseases.
  • Intravenous (IV) Infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and how these effects relate to drug concentration.
  • Biomarkers: Measurable indicators of a biological state or condition, often used to track disease progression or treatment effectiveness.
  • MRI (Magnetic Resonance Imaging): A medical imaging technique that uses magnetic fields and radio waves to create detailed images of organs and tissues in the body.
  • PET (Positron Emission Tomography): An imaging test that uses a radioactive tracer to visualize how organs and tissues are functioning in the body.
  • ARIA (Amyloid-Related Imaging Abnormalities): Brain imaging findings associated with some Alzheimer's disease treatments, which can include swelling (ARIA-E) or small areas of bleeding (ARIA-H) in the brain.
  • Study Partner: A person who has frequent contact with the participant and can provide accurate information about the participant's cognitive and functional abilities during the study.

References

  1. http://clinicaltrials.eu/trial/study-on-the-long-term-safety-and-effects-of-al002-and-florquinitau-f18-in-patients-with-alzheimers-disease/